Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -8.17
- Piotroski Score 2.00
- Grade Buy
- Symbol (GTHX)
- Company G1 Therapeutics, Inc.
- Price $7.16
- Changes Percentage (0.14%)
- Change $0.01
- Day Low $7.14
- Day High $7.16
- Year High $7.19
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/29/2024
- Fiscal Year End N/A
- Average Stock Price Target $4.50
- High Stock Price Target $6.00
- Low Stock Price Target $3.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.60
- Trailing P/E Ratio -5.02
- Forward P/E Ratio -5.02
- P/E Growth -5.02
- Net Income $-47,967,000
Income Statement
Quarterly
Annual
Latest News of GTHX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
G1 Therapeutics, Inc.'s (NASDAQ:GTHX) top owners are retail investors with 56% stake, while 28% is held by institutions
Retail investors hold 56% ownership in G1 Therapeutics, influencing key decisions. Institutional investors own 28%, while insiders and hedge funds have smaller stakes. Top shareholders collectively ow...
By Yahoo! Finance | 3 months ago
